What is the Study about?
The purpose of this study is to evaluate whether finerenone is effective and safe in reducing the incidence of cardiovascular events in patients with type 2 diabetes and diabetic kidney disease. Type 2 diabetes is a chronic disease in which the body is unable to properly use insulin, a hormone that regulates blood sugar levels, or does not produce enough insulin, typically leading to increased blood sugar levels and other complications. Along with diabetic kidney disease, cardiovascular disease is a common and major complication affecting patients with type 2 diabetes. This study will look at the number of cardiovascular events in participants with type 2 diabetes and diabetic kidney disease and compare these rates among patients receiving finerenone or placebo.
Eligibility to participate
- Are between the age of 18 – 70 years
- Have type 2 diabetes
- Have diabetic kidney disease
What is involved in the Study?
Participants will be randomly assigned (like the flip of a coin) to receive either finerenone or a placebo and come to the University of Minnesota for 12 visits over 3 years. At these visits medical history will be reviewed, an electrocardiogram (ECG) taken, and blood and urine collected for laboratory testing. Compensation is available.